Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology)

N/A

Report date: 2024/12/20 16:51:09

Base Information

Drug NameCord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology)
Drug Alias Namecord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 therapy(Rongu Biotechnology)CB CAR-NK182RG-CLDN18.2
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Rongu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Rongu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A